Medicus Pharma Ltd. Engages in Share Transactions: Issues 490,000 Shares to Yorkville and Sells 1,340,000 Warrants with New Inducement Agreement

Reuters
14 Jul
<a href="https://laohu8.com/S/MDCX">Medicus Pharma Ltd.</a> Engages in Share Transactions: Issues 490,000 Shares to Yorkville and Sells 1,340,000 Warrants with New Inducement Agreement

Medicus Pharma Ltd. recently engaged in share transactions with YA II PN, Ltd. (Yorkville) under a Standby Equity Purchase Agreement $(SEPA)$. On July 9 and July 14, 2025, the company sold a total of 490,000 common shares to Yorkville. The shares were sold at approximately $3.2841 and $3.0216 per share, amounting to total proceeds of approximately $1,521,000. Additionally, the company entered into an inducement agreement with an accredited holder to exercise existing warrants for up to 1,340,000 shares, generating gross proceeds of approximately $3.75 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-25-012767), on July 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10